Term |
Definition |
Atypical intraepidermal melanocytic variant |
Unusual area of darker pigmentation contained within the epidermis that may progress to an invasive melanoma; includes melanoma in situ and lentigo maligna |
Atypical naevi |
Unusual looking but non‐cancerous mole or area of darker pigmentation of the skin |
BRAF V600 mutation |
BRAF is a human gene that makes a protein called B‐Raf which is involved in the control of cell growth. BRAF mutations (damaged DNA) occur in around 40% of melanomas, which can then be treated with particular drugs. |
BRAF inhibitors |
Therapeutic agents that inhibit the serine‐threonine protein kinase BRAF mutated metastatic melanoma. |
Breslow thickness |
A scale for measuring the thickness of melanomas by the pathologist using a microscope, measured in mm from the top layer of skin to the bottom of the tumour |
Congenital naevi |
A type of mole found on infants at birth |
Dermoscopy |
Whereby a handheld microscope is used to allow more detailed, magnified, examination of the skin compared to examination by the naked eye alone |
False negative |
An individual who is truly positive for a disease, but whom a diagnostic test classifies them as disease‐free |
False positive |
An individual who is truly disease‐free, but whom a diagnostic test classifies them as having the disease |
Histopathology/Hhistology |
The study of tissue, usually obtained by biopsy or excision, for example under a microscope |
Incidence |
The number of new cases of a disease in a given time period |
Index test |
A diagnostic test under evaluation in a primary study |
Lentigo maligna |
Unusual area of darker pigmentation contained within the epidermis which includes malignant cells but with no invasive growth. May progress to an invasive melanoma |
Lymph node |
Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells) that travels around the body to help fight disease; they are located throughout the body often in clusters (nodal basins). |
Melanocytic naevus |
An area of skin with darker pigmentation (or melanocytes), also referred to as moles |
Meta‐analysis |
A form of statistical analysis used to synthesise results from a collection of individual studies |
Metastases/metastatic disease |
Spread of cancer away from the primary site to somewhere else through the bloodstream or the lymphatic system |
Micrometastases |
Micrometastases are metastases so small that they can only be seen under a microscope |
Mitotic rate |
Microscopic evaluation of number of cells actively dividing in a tumour |
Morbidity |
Detrimental effects on health |
Mortality |
Either the condition of being subject to death; or the death rate, which reflects the number of deaths per unit of population in relation to any specific region, age group, disease, treatment or other classification, usually expressed as deaths per 100, 1000, 10,000 or 100,000 people |
Multidisciplinary team |
A team with members from different healthcare professions and specialties (e.g. urology, oncology, pathology, radiology, and nursing). Cancer care in the National Health Service (NHS) uses this system to ensure that all relevant health professionals are engaged to discuss the best possible care for that patient. |
Prevalence |
The proportion of a population found to have a condition |
Prognostic factors/indicators |
Specific characteristics of a cancer or the person who has it which might affect the patient's prognosis |
Receiver operating characteristic (ROC) plot |
A plot of the sensitivity and 1 minus the specificity of a test at the different possible thresholds for test positivity; represents the diagnostic capability of a test with a range of binary test results |
Receiver operating characteristic (ROC) analysis |
The analysis of a ROC plot of a test to select an optimal threshold for test positivity |
Recurrence |
Recurrence is when new cancer cells are detected following treatment. This can occur either at the site of the original tumour or at other sites in the body. |
Reference standard |
A test or combination of tests used to establish the final or 'true' diagnosis of a patient in an evaluation of a diagnostic test |
Reflectance confocal microscopy (RCM) |
A microscopic technique using infrared light (either in a handheld device or a static unit) that can create images of the deeper layers of the skin |
Sensitivity |
In this context the term is used to mean the proportion of individuals with a disease who have that disease correctly identified by the study test |
Specificity |
The proportion of individuals without the disease of interest (in this case with benign skin lesions) who have that absence of disease correctly identified by the study test |
Staging |
Clinical description of the size and spread of a patient's tumour, fitting into internationally agreed categories |
Subclinical (disease) |
Disease that is usually asymptomatic and not easily observable, e.g. by clinical or physical examination |
Systemic treatment |
Treatment, usually given by mouth or by injection, that reaches and affects cancer cells throughout the body rather than targeting one specific area |